Redwood Bioscience
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Redwood Bioscience - overview
Established
2008
Location
Emeryville, CA, US
Primary Industry
Biotechnology
About
Redwood Bioscience focuses on the development of E. coli recombinant proteins, utilizing advanced glycoproteomics for therapeutic applications. The company's work significantly enhances protein stability, efficacy, and cellular interactions in drug development and bioconjugation. Founded in 2008 in Emeryville, US, Redwood Bioscience specializes in creating E.
coli recombinant proteins for therapeutic uses. The company notably underwent a strategic change in October 2014 when Catalent acquired the remaining stake in Redwood Bioscience. The total amount raised by the company is USD 2. 50 mn through its Series B funding round, making it the final round of funding.
The firm has completed 7 deals, with its most recent deal occurring on October 2, 2014. Redwood Bioscience specializes in developing E. coli recombinant proteins, leveraging advanced glycoproteomics to support therapeutic applications. Core offerings include glycoprotein analysis, aiding in the understanding of glycosylation processes that impact protein stability and efficacy.
Their products cater to drug development, bioconjugation, and monoclonal antibody formation, serving pharmaceutical companies, biotechnology firms, and academic institutions primarily in North America, Europe, and parts of Asia. The company's revenue derives from direct sales of E. coli recombinant protein products and glycoproteomics services through B2B agreements with biotech and pharmaceutical clients. Their pricing model aligns with project scope, ensuring tailored solutions.
Key offerings encompass specialized glycoprotein analysis services and proprietary glycosylation profiling techniques, aimed at supporting diverse therapeutic development goals in the life sciences sector. Redwood Bioscience's future growth strategy includes the design and launch of new products to expand their glycoproteomics service offerings, with anticipated releases in upcoming fiscal years. The company aims to penetrate new markets in Europe and Asia by 2025. The USD 2.
50 mn raised from its most recent funding round will be allocated towards enhancing research capabilities and expanding market reach, facilitating the development of innovative solutions to meet evolving industry needs.
Current Investors
Blackstone Group, Genstar Capital Partners, Catalent, Inc.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.redwoodbioscience.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Redwood Bioscience - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Redwood Bioscience | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.